阿托伐他汀钙治疗急性脑梗死的效果与安全性分析

Analysis of the effect and safety of atorvastatin calcium in the treatment of acute cerebral infarction

目的评价急性脑梗死(ACI)患者行阿托伐他汀钙治疗的预后效果及药物安全性。方法选择106例ACI患者,以随机法分为对照组(n=53,采取辛伐他汀治疗)和观察组(n=53,采取阿托伐他汀钙片治疗)。比较两组临床疗效、药物不良反应发生情况、神经功能缺损程度以及康复情况。结果观察组治疗总有效率96.23%高于对照组的81.13%,差异显著(P<0.05)。两组药物不良反应发生率比较,差异无统计学意义(P>0.05)。两组治疗后美国国立卫生研究院卒中量表(NIHSS)评分均较治疗前低,且观察组NIHSS评分(4.55±1.20)分低于对照组的(5.60±1.40)分,差异显著(P<0.05)。两组治疗后氧化型低密度脂蛋白(ox-LDL)、超敏C反应蛋白(hs-CRP)水平均低于治疗前,且观察组治疗后ox-LDL(46.78±4.45)μg/dl、hs-CRP(3.22±1.01)mg/L均低于对照组的(57.32±4.55)μg/dl、(8.72±1.20)mg/L,差异显著(P<0.05)。结论阿托伐他汀钙片治疗ACI具有安全性、有效性,能促进患者神经功能改善、临床恢复。

Objective To evaluate the prognostic effect and safety of atorvastatin calcium in the treatment of acute cerebral infarction(ACI).Methods 106 ACI patients were selected and randomly divided into a control group(n=53,treated with simvastatin)and an observation group(n=53,treated with atorvastatin calcium tablets).The clinical efficacy,adverse drug reactions,degree of neurological impairment,and rehabilitation were compared between the two groups.Results The total effective rate of the observation group was 96.23%,which was higher than 81.13%of control group,and the difference was significant(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).After treatment,the National Institutes of Health Stroke Scale(NIHSS)score in both groups was lower than that before treatment,and the NIHSS score of(4.55±1.20)points in the observation group was lower than(5.60±1.40)points in the control group.The difference was significant(P<0.05).After treatment,the levels of oxidized low-density lipoprotein(ox-LDL)and hypersensitive C-reactive protein(hs-CRP)in both groups were lower than those before treatment;the observation group had ox-LDL of(46.78±4.45)μg/dl and hs-CRP of(3.22±1.01)mg/L,which were lower than(57.32±4.55)μg/dl and(8.72±1.20)mg/L in the control group;the difference was significant(P<0.05).Conclusion Atorvastatin calcium tablets are safe and effective in the treatment of ACI,and can promote the improvement of neurological function and clinical recovery in patients.